birelentinib + venetoclax

birelentinib + venetoclax is a combination therapy consisting of birelentinib (a small molecule inhibitor, also known as EQS-110, that selectively targets neurotrophic tyrosine kinase receptors) and venetoclax (a potent oral BCL-2 inhibitor). Venetoclax induces apoptosis in cancer cells by inhibiting the anti-apoptotic protein BCL-2, leading to cell death. Birelentinib, though not as widely established as venetoclax, is characterized as a targeted kinase inhibitor against Trk family neurotrophic receptors. This combination is being evaluated for synergistic antitumor effects, particularly in hematologic malignancies where BCL-2 dependence is prominent and Trk signaling has been implicated. Combination regimens like these are designed to block multiple pathways critical for cancer cell survival, potentially overcoming resistance to monotherapy and enhancing the induction of apoptosis. Venetoclax is developed and manufactured by AbbVie, and birelentinib's developer is Equillium.

Other names

birelentinibvenetoclax